Drug Manufacturers

Features

ADCs breach barriers to become mainstream cancer treatment

Manufacturing practices are evolving to advance antibody drug conjugates (ADCs) for cancer treatment through a targeted approach.

Natasha Spencer-Jolliffe

News

The course to forging long-term manufacturing partnerships for gene therapies

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close

Sections

Sections

Sections

Sections

Sections

ADCs breach barriers to become mainstream cancer treatment

The course to forging long-term manufacturing partnerships for gene therapies

Leading lead generation providers and technology solutions for the clinical trials industry

Leading sales enablement, prospecting and automation providers and technology solutions for the clinical trials industry

Sign up for our daily news round-up!

Sign up to the newsletter: In Brief

Sign up for our daily news round-up!

Sign up for our daily news round-up!

Sign up to the newsletter: In Brief

I would also like to subscribe to:

Thank you for subscribing